{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:37:59Z","timestamp":1790800679774,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Patients with giant cell arteritis (GCA) face an increased risk of major adverse cardiovascular events (MACE). The benefit of low-dose aspirin in these patients is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the 1-year association of low-dose aspirin with risk of MACE in primary prevention in patients with incident GCA and to evaluate the risk of major hemorrhage and net clinical benefit at predefined time points.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study used a target trial emulation framework with a cloning, censoring, and weighting approach within the French National Health Data System. Participants were individuals aged at least 50 years with incident GCA between 2010 and 2022, without previous cardiovascular events or antiplatelet or anticoagulant use at GCA diagnosis. Analysis was conducted from November 2024 to June 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Initiation of low-dose aspirin vs not (control group) within 14 days of GCA diagnosis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was MACE, a composite end point of ischemic stroke, myocardial infarction, and all-cause mortality. Major hemorrhages were evaluated as secondary outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 14\u202f528 individuals (median [IQR] age, 74 [67 to 80] years; 10\u202f396 [72%] female), were included. Low-dose aspirin was initiated in 5220 individuals (36%). At 1 year, MACE risk was lower in the low-dose aspirin group (relative risk [RR], 0.86 [95% CI, 0.75 to 0.96]; risk difference [RD], \u22120.54% [95% CI, \u22120.99% to \u22120.12%]), while major hemorrhage risk was higher (RR, 1.29 [95% CI, 1.05 to 1.53]; RD, 0.51% [95% CI, 0.13% to 0.91%]). All-cause mortality was lower in the low-dose aspirin group at 1 year (RD, \u22120.43% [95% CI, \u22120.77% to \u22120.10%]). At 3 years, MACE events were less frequent in the low-dose aspirin group (RD, \u22121.08% [95% CI, \u22121.77% to \u22120.41%]), with no difference in major hemorrhages. A more pronounced association between low-dose aspirin and lower 1-year MACE was observed in women (RD, \u22120.78% [95% CI, \u22121.29% to \u22120.25%]) and patients with diabetes at GCA diagnosis (RD, \u22122.23% [95% CI, \u22123.48% to \u22121.02%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this retrospective cohort study, low-dose aspirin at GCA diagnosis was associated with lower MACE at 1 and 3 years but higher hemorrhage risk at 1 year. Subgroup analyses suggested heterogeneity according to sex and diabetic status.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.6579","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:30:37Z","timestamp":1776439837000},"page":"e266579","source":"Crossref","is-referenced-by-count":2,"title":["Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis"],"prefix":"10.1001","volume":"9","author":[{"given":"Maxime","family":"Beydon","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut pour la Sant\u00e9 et la Recherche M\u00e9dicale, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hajage","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut pour la Sant\u00e9 et la Recherche M\u00e9dicale, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis F.","family":"Gu\u00e9don","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Saint-Antoine, Assistance Publique - H\u00f4pitaux de Paris, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, D\u00e9partement de sant\u00e9 publique, H\u00f4pital Saint-Antoine, Assistance Publique - H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Bic\u00eatre, Assistance Publique - H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"},{"name":"Center for Immunology of Viral Infections and Auto-immune Diseases, Institut pour la Sant\u00e9 et la Recherche M\u00e9dicale UMR 1184, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut pour la Sant\u00e9 et la Recherche M\u00e9dicale, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Equipe PEPITES, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"10354","key":"zoi260223r1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"zoi260223r2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/M12-3046","article-title":"Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study.","volume":"160","author":"Tomasson","year":"2014","journal-title":"Ann Intern Med"},{"key":"zoi260223r3","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag034","article-title":"Cardiovascular risk among giant cells arteritis patients.","volume":"14","author":"Guedon","year":"2026","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"zoi260223r4","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"zoi260223r5","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"zoi260223r6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis.","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"zoi260223r7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.autrev.2014.02.006","article-title":"Effect of antiplatelet\/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis.","volume":"13","author":"Mart\u00ednez-Taboada","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"zoi260223r8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis.","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi260223r9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.revmed.2024.10.011","article-title":"French protocol for the diagnosis and management of giant cell arteritis.","volume":"46","author":"de Boysson","year":"2025","journal-title":"Rev Med Interne"},{"issue":"16","key":"zoi260223r10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"10152","key":"zoi260223r11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"zoi260223r12","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement.","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"issue":"34","key":"zoi260223r13","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi260223r14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"zoi260223r15","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"12","key":"zoi260223r16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent Reporting of Observational Studies Emulating a Target Trial\u2014the TARGET Statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"zoi260223r17","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France.","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"6","key":"zoi260223r18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase.","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapie"},{"issue":"6","key":"zoi260223r19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/fcp.12143","article-title":"Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database.","volume":"29","author":"Bezin","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"zoi260223r20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12874-019-0841-6","article-title":"Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department.","volume":"19","author":"Oger","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"zoi260223r21","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.ejim.2018.10.004","article-title":"Validation of giant cell arteritis diagnosis code in the French hospital electronic database.","volume":"60","author":"Caudrelier","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"10","key":"zoi260223r22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2024.06.022","article-title":"Antithrombotic strategies in atrial fibrillation after ACS and\/or PCI: a 4-way comparison from AUGUSTUS.","volume":"84","author":"Berwanger","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"zoi260223r23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease.","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260223r24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death.","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"issue":"5","key":"zoi260223r25","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias: assessing the benefit of major surgery for elderly lung cancer patients using observational data.","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"5","key":"zoi260223r26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2188\/jea.JE20150123","article-title":"Bowel movement frequency, laxative use, and mortality from coronary heart disease and stroke among Japanese men and women: the Japan Collaborative Cohort (JACC) Study.","volume":"26","author":"Kubota","year":"2016","journal-title":"J Epidemiol"},{"key":"zoi260223r27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2018.12.021","article-title":"Constipation and risk of death and cardiovascular events.","volume":"281","author":"Sumida","year":"2019","journal-title":"Atherosclerosis"},{"issue":"16","key":"zoi260223r28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus.","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi260223r29","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events.","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi260223r30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"zoi260223r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.10144","article-title":"Aspirin for primary prevention\u2014time to rethink our approach.","volume":"5","author":"Berger","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260223r32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jama.2019.8388","article-title":"A practical approach to low-dose aspirin for primary prevention.","volume":"322","author":"Chiang","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"zoi260223r33","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1093\/rheumatology\/keaf164","article-title":"Association between cardiovascular risk factors and the occurrence of giant cell arteritis: a systematic review and meta-analysis.","volume":"64","author":"Barde","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"zoi260223r34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1747493019858780","article-title":"Aspirin for primary prevention of stroke in individuals without cardiovascular disease\u2014a meta-analysis.","volume":"15","author":"Judge","year":"2020","journal-title":"Int J Stroke"},{"issue":"16","key":"zoi260223r35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260223r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.29104","article-title":"Participation of women in cardiovascular trials from 2017 to 2023: a systematic review.","volume":"8","author":"Rivera","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260223r37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force.","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann Intern Med"},{"issue":"22","key":"zoi260223r38","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2024-324625","article-title":"Advancing the access to cardiovascular diagnosis and treatment among women with cardiovascular disease: a joint British Cardiovascular Societies\u2019 consensus document.","volume":"110","author":"Tayal","year":"2024","journal-title":"Heart"},{"issue":"6","key":"zoi260223r39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0033354917736514","article-title":"Death certification errors and the effect on mortality statistics.","volume":"132","author":"McGivern","year":"2017","journal-title":"Public Health Rep"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847872\/beydon_2026_oi_260223_1775848021.335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:30:38Z","timestamp":1776439838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.6579","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}